Integrated Filing — IndAS



General information about company

Scrip Code 539523
NSE Symbol ALKEM
MSEI Symbol NOTLISTED
ISIN INE540L01014
Name of company ALKEM LABORATORIES LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 28-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 19-05-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment The Company is exclusively engaged in pharmaceutical business
Start date and time of board meeting 28-05-2026   11:20:00
End date and time of board meeting 28-05-2026   13:15:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 13-02-2026
Indicate Company website link for updated RPT policy of the Company https://admin.alkemlabs.com/uploads/Related_Party_Transactions_Policy_1e79a77a4a.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
No defaults on loan and debt securities



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Unaudited Audited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 2,25,844.00 9,66,391.00
Other income 20,569.00 55,517.00
Total income 2,46,413.00 10,21,908.00
2 Expenses
(a) Cost of materials consumed 65,886.00 2,42,933.00
(b) Purchases of stock-in-trade 10,750.00 42,695.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (6,667.00) (4,567.00)
(d) Employee benefit expense 46,686.00 1,88,303.00
(e) Finance costs 1,624.00 5,729.00
(f) Depreciation, depletion and amortisation expense 7,817.00 25,656.00
(f) Other Expenses
1 Other Expenses 74,787.00 2,54,588.00
Total other expenses 74,787.00 2,54,588.00
Total expenses 2,00,883.00 7,55,337.00
3 Total profit before exceptional items and tax 45,530.00 2,66,571.00
4 Exceptional items (11,921.00) (14,309.00)
5 Total profit before tax 33,609.00 2,52,262.00
6 Tax expense
7 Current tax 7,471.00 43,200.00
8 Deferred tax 4,432.00 (9,450.00)
9 Total tax expenses 11,903.00 33,750.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 21,706.00 2,18,512.00
12 Profit (loss) from discontinued operations before tax 0.00 14,905.00
13 Tax expense of discontinued operations 0.00 5,208.00
14 Net profit (loss) from discontinued operation after tax 0.00 9,697.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 21,706.00 2,28,209.00
17 Other comprehensive income net of taxes 1,850.00 462.00
18 Total Comprehensive Income for the period 23,556.00 2,28,671.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 2,391.00 2,391.00
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve 0.00
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 18.16 182.76
Diluted earnings (loss) per share from continuing operations 18.16 182.76
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 8.11
Diluted earnings (loss) per share from discontinued operations 0 8.11
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 18.16 190.87
Diluted earnings (loss) per share from continuing and discontinued operations 18.16 190.87
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1.The above standalone financial results are prepared in accordance with the lndian Accounting Standards prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). 2.The above standalone financial results of the Company were reviewed and recommended by the Audit Committee on 27 May 2026 and subsequently approved by the Board of Directors at its meeting held on 28 May 2026. The auditors have expressed an unmodified opinion on the financial results for the year ended 31 March 2026. The figures for the quarter ended 31 March 2026 and 31 March 2025 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevant financial year. 3.The Board of Directors of the Company at their meeting held on 10 December 2024 had approved the transfer of Generic Business Undertaking to Alkem Wellness Limited, a wholly owned subsidiary of the Company as a going concern, on a slump sale basis. The Company has executed a Business Transfer Agreement (BTA), effective 01 October 2025, and transferred its Generic business to Alkem Wellness Limited. During the earlier periods, the transfer of the Generic Business had been disclosed as discontinued operations in accordance with Ind AS 105 Non - current Assets Held for Sale and Discontinued Operations. The figures for the previous periods have been restated to give effect to the presentation requirement of Ind AS 105 Non - current Assets Held for Sale and Discontinued Operations. Key financial information of Discontinued Operations: Quarter ended 31.03.2026 Total Income : Nil Total expenses : Nil Profit before tax : Nil Total tax expense : Nil Net profit for the period : Nil Quarter ended 31.12.2025 Total Income : Nil Total expenses : Nil Profit before tax : Nil Total tax expense : Nil Net profit for the period : Nil Quarter ended 31.03.2025 Total Income : 5,190.5 Total expenses : 4,405.7 Profit before tax : 784.8 Total tax expense : 274.2 Net profit for the period : 510.6 Year ended 31.03.2026 Total Income : 9,181.0 Total expenses : 7,690.5 Profit before tax : 1,490.5 Total tax expense : 520.8 Net profit for the period : 969.7 Year ended 31.03.2025 Total Income : 18,974.9 Total expenses : 16,036.4 Profit before tax : 2,938.5 Total tax expense : 1,026.8 Net profit for the period : 1,911.7 *Note: The figures for the year ended 31 March 2026 are not comparable with those of the corresponding period, as they reflect carved-out results up to 30 September 2025, the date on which the generic business was transferred to Alkem Wellness Limited. 4. Exceptional items include: 1) During the quarter and year ended 31 March 2026 year, the Company reviewed its investments in real estate; where recoverability is subject to uncertainties. Accordingly, management has reassessed the carrying value of such investments and recognised a provision for impairment amounting to Rs 747 million, which has been disclosed as an exceptional item for the quarter and year ended March 31, 2026 2) During the year, pursuant to the notification and subsequent finalisation of the Central Rules under the Labour Codes by the Government of India, the Company assessed the financial impact of the revised regulatory framework, including the Code on Social Security, 2020, based on detailed evaluation of the notified provisions, professional advice, and actuarial valuation. Based on this assessment, the Company recognised an estimated liability towards gratuity and leave encashment for past service cost aggregating to Rs 381.7 million in the quarter ended 31 December 2025 and an incremental impact of Rs 445.1 million in the quarter ended 31 March 2026 resulting in a total impact of Rs 826.8 million for the year ended 31 March 2026. The total impact has been disclosed as an exceptional item in the financial results. The Company will continue to evaluate any further clarifications or implementation guidance issued in relation to the Labour Codes and account for the financial impact, if any, as appropriate. 3) The Company as part of its ongoing initiative of networking, strategy and optimisation of manufacturing facilities had identified divestment of its Indore facility and had impaired the same during financial year 2024. The said facility has been sold in the quarter ended 30 June 2025 in accordance with the business transfer agreement entered with the buyer. The resulting gain (arising out of reversal of impairment loss) amounting to Rs142.9 million had been classified and disclosed as an exceptional item in the results for the year ended 31 March 2026. 5.Pursuant to the amendments introduced under the Finance Act, 2026, interalia allowing set off of available MAT credit under new tax regime (Section 115BAA of the Income-tax Act, 1961), the Company has decided to opt for the new tax regime from financial year 2026 – 27. Consequently, deferred tax has been recognised at the substantially enacted rate as at 31 March 2026. 6.The Board of Directors at its meeting held on 28 May 2026 have declared a final dividend of Rs 10 (Rupees Ten only) per equity share (face value of Rs 2 each) in addition to the interim dividend Rs 43 (Rupees Forty Three only) per equity share (face value of Rs 2 each) declared on 13 February 2026. The final dividend is subject to approval at the ensuing annual general meeting of the Company. 7.The Company operates in one reportable business segment i.e. Pharmaceuticals, accordingly no separate disclosure of segment information has been made.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 31-03-2026
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 1,42,239.00
Capital work-in-progress 8,627.00
Investment property 0.00
Goodwill 0.00
Other intangible assets 12,712.00
Intangible assets under development 3,651.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 5,01,078.00
Trade receivables, non-current 0.00
Loans, non-current 992.00
Other non-current financial assets
1 Other Financial assets 1,02,519.00
Total of other non-current financial assets 1,02,519.00
Total non-current financial assets 6,04,589.00
Deferred tax assets (net) 1,52,209.00
Other non-current assets
1 Current tax assets (net) 3,272.00
2 Other non-current assets 15,802.00
Total of other non-current assets 19,074.00
Total non-current assets 9,43,101.00
2 Current assets
Inventories 1,63,176.00
Current financial asset
Current investments 54,115.00
Trade receivables, current 1,56,724.00
Cash and cash equivalents 6,545.00
Bank balance other than cash and cash equivalents 1,22,402.00
Loans, current 142.00
Other current financial assets
Total of other current financial assets 2,10,831.00
Total current financial assets 5,50,759.00
Current tax assets (net) 0.00
Other current assets
1 Other current assets 69,077.00
Total of other current assets 69,077.00
Total current assets 7,83,012.00
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 17,26,113.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 2,391.00
Other equity 13,97,485.00
Total equity attributable to owners of parent 13,99,876.00
Non controlling interest
Total equity 13,99,876.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Other non-current financial liabilities 16,030.00
Total of other non-current financial liabilities 16,030.00
Total non-current financial liabilities 16,030.00
Provisions, non-current 33,810.00
Deferred tax liabilities (net) 0.00
Deferred government grants, Non-current 0.00
Other non-current liabilities
1 Other non-current liabilities 1,716.00
Total of other non-current liabilities 1,716.00
Total non-current liabilities 51,556.00
Current liabilities
Current financial liabilities
Borrowings, current 53,924.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 7,921.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 1,39,692.00
Total Trade payable 1,47,613.00
Other current financial liabilities
1 Other current financial liabilities 39,964.00
2 Lease liabilities 1,725.00
Total of other current financial liabilities 41,689.00
Total current financial liabilities 2,43,226.00
Other current liabilities 10,619.00
1 Other current liabilities 10,619.00
Total of other current liabilities 10,619.00
Provisions, current 16,741.00
Current tax liabilities (Net) 4,095.00
Deferred government grants, Current 0.00
Total current liabilities 2,74,681.00
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 3,26,237.00
Total equity and liabilites 17,26,113.00
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-01-2026 01-04-2025
Date of end of reporting period 31-03-2026 31-03-2026
Whether results are audited or unaudited Unaudited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Unaudited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 In respect of continuing operations: 2,750.00 653.00
2 In respect of discontinued operations: 0.00 (36.00)
Total Amount of items that will not be reclassified to profit and loss 2,750.00 617.00
2 Income tax relating to items that will not be reclassified to profit or loss 900.00 155.00
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income 1,850.00 462.00



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 31-03-2026
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 2,52,262.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 5,861.00
Adjustments for decrease (increase) in inventories (14,978.00)
Adjustments for decrease (increase) in trade receivables, current 4,565.00
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (14,616.00)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current (221.00)
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 0.00
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 26,078.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 9,640.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (446.00)
Adjustments for dividend income 0.00
Adjustments for interest income 33,580.00
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) 1,010.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 10,296.00
Other adjustments for non-cash items 0.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (6,391.00)
Net cash flows from (used in) operations 2,45,871.00
Dividends received (408.00)
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 48,148.00
Other inflows (outflows) of cash (403.00)
Net cash flows from (used in) operating activities 1,96,912.00
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 12,966.00
Purchase of property, plant and equipment 27,727.00
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 4,78,550.00
Purchase of other long-term assets 6,37,904.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 408.00
Interest received 27,179.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 403.00
Net cash flows from (used in) investing activities (1,46,125.00)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 264.00
Repayments of borrowings 0.00
Payments of lease liabilities 2,308.00
Dividends paid 60,978.00
Interest paid 4,260.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (67,282.00)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (16,495.00)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents (16,495.00)
Cash and cash equivalents cash flow statement at beginning of period 1,204.00
Cash and cash equivalents cash flow statement at end of period (15,291.00)





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Deloitte Haskins & Sells LLP Yes 31-07-2027


Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 S&B Pharma LLC The Pharma Network LLC Subsidiary Sale of goods or services Not Applicable 5,528.50 3,562.60 484.00
2 The Pharma Network LLC S&B Pharma LLC Subsidiary Any other transaction Reimbursement of expenses by us Not Applicable 82.20 0.00 0.00
3 Pharmacor Pty Limited Alkem Laboratories Corporation Fellow Subsidiary Company Any other transaction Reimbursement of expenses by us Not Applicable 15.30 14.40 15.00
4 Alkem Laboratories Limited Mr Aniruddha Singh Relative of Key Management Personnel Remuneration As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 18.80 0.00 0.00
5 Alkem Laboratories Limited Mr Basudeo Narain Singh Key Management Personnel Remuneration As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 1,060.50 0.00 0.00
6 Alkem Laboratories Limited Cachet Pharmaceuticals Private Limited Subsidiary Purchase of goods or services 40,000.00 Approved by the audit committee of the entity 431.60 1,708.50 178.30
7 Alkem Laboratories Limited Cachet Pharmaceuticals Private Limited Subsidiary Any other transaction Services received 1,000.00 Approved by the audit committee of the entity 6.90 1,708.50 178.30
8 Alkem Laboratories Limited Cachet Pharmaceuticals Private Limited Subsidiary Any other transaction Royalty expenses 1,000.00 Approved by the audit committee of the entity 1.10 1,708.50 178.30
9 Alkem Laboratories Limited Cachet Pharmaceuticals Private Limited Subsidiary Any other transaction Rent Income 500.00 Approved by the audit committee of the entity 21.40 0.00 170.00
10 Alkem Laboratories Limited Cachet Pharmaceuticals Private Limited Subsidiary Any other transaction Reimbursement of Expenses by us 2,000.00 Approved by the audit committee of the entity 1.80 0.00 0.00
11 Alkem Laboratories Limited Alkem Laboratories Corporation Subsidiary Sale of goods or services 1,000.00 Approved by the audit committee of the entity (89.80) 315.70 0.00
12 Alkem Laboratories Limited Alkem Laboratories Korea Inc. Subsidiary Interest received As per approval of Board of Directors or Shareholders of the entity as necessary 0.50 24.30 25.40
13 Alkem Laboratories Limited Ascend GmbH Subsidiary Sale of goods or services 30,000.00 Approved by the audit committee of the entity 10,741.90 8,267.30 8,143.40
14 Alkem Laboratories Limited Ascend GmbH Subsidiary Any other transaction Guarantee commission 200.00 Approved by the audit committee of the entity 0.50 0.00 0.00
15 Alkem Laboratories Limited Ascend GmbH Subsidiary Any other transaction Reimbursement of expenses by us 2,400.00 Approved by the audit committee of the entity 199.40 592.40 205.10
16 Alkem Laboratories Limited Ascend Laboratories (Pty) Ltd Subsidiary Sale of goods or services 2,000.00 Approved by the audit committee of the entity 573.20 977.00 445.90
17 Alkem Laboratories Limited Ascend Laboratories (Pty) Ltd Subsidiary Any other transaction Guarantee commission 100.00 Approved by the audit committee of the entity 0.00 0.00 0.00
18 Alkem Laboratories Limited Ascend Laboratories (Pty) Ltd Subsidiary Any other transaction Services rendered 0.50 Ratified by the audit committee of the entity 0.50 27-05-2026 0.50 0.00 0.00
19 Alkem Laboratories Limited Ascend Laboratories (UK) Limited Subsidiary Sale of goods or services 11,400.00 Approved by the audit committee of the entity 2,165.70 5,042.20 1,772.40
20 Alkem Laboratories Limited Ascend Laboratories (UK) Limited Subsidiary Any other transaction Guarantee commission 100.00 Approved by the audit committee of the entity 1.00 0.00 0.00
21 Alkem Laboratories Limited Ascend Laboratories (UK) Limited Subsidiary Any other transaction Reimbursement of expenses by us 800.00 Approved by the audit committee of the entity 64.30 579.40 200.70
22 Alkem Laboratories Limited Ascend Laboratories S.A. DE. CV Step down subsidiary Any other transaction Reimbursement of expenses by us 500.00 Approved by the audit committee of the entity 0.00 118.10 155.00
23 Alkem Laboratories Limited Ascend Laboratories SAS Subsidiary Sale of goods or services 5,000.00 Approved by the audit committee of the entity 3,695.60 1,701.80 3,850.90
24 Alkem Laboratories Limited Ascend Laboratories SAS Subsidiary Any other transaction Services rendered 1,500.00 Approved by the audit committee of the entity 48.20 0.00 3,850.90
25 Alkem Laboratories Limited Ascend Laboratories SAS Subsidiary Any other transaction Guarantee commission 100.00 Approved by the audit committee of the entity 0.20 0.00 0.00
26 Alkem Laboratories Limited Ascend Laboratories SAS Subsidiary Any other transaction Reimbursement of expenses by us 200.00 Approved by the audit committee of the entity 82.80 0.00 103.90
27 Alkem Laboratories Limited Ascend Laboratories SDN BHD. Subsidiary Any other transaction Reimbursement of expenses by us 50.00 As per approval of Board of Directors or Shareholders of the entity as necessary 0.40 0.00 12.20
28 Alkem Laboratories Limited Ascend Laboratories SDN BHD. Subsidiary Interest received As per approval of Board of Directors or Shareholders of the entity as necessary 3.60 0.00 3.60
29 Alkem Laboratories Limited Alkem Laboratories Corporation Subsidiary Interest received As per approval of Board of Directors or Shareholders of the entity as necessary 26.20 0.00 948.00
30 Alkem Laboratories Limited Alkem Laboratories Corporation Subsidiary Any other transaction Reimbursement of Expenses by party 500.00 Approved by the audit committee of the entity 11.50 0.00 7.80
31 Alkem Laboratories Limited Alkem Laboratories Corporation Subsidiary Any other transaction Guarantee commission 100.00 Approved by the audit committee of the entity 0.60 0.00 0.00
32 Alkem Laboratories Limited Ascend Laboratories SpA Subsidiary Sale of goods or services 40,000.00 Approved by the audit committee of the entity 9,481.30 7,487.70 8,318.80
33 Alkem Laboratories Limited Ascend Laboratories SpA Subsidiary Any other transaction Guarantee commission 100.00 Approved by the audit committee of the entity 26.30 0.00 0.00
34 Alkem Laboratories Limited Ascend Laboratories SpA Subsidiary Any other transaction Services rendered 500.00 Approved by the audit committee of the entity 94.20 7,487.70 8,318.80
35 Alkem Laboratories Limited Ascend Laboratories S.A. DE. CV Step down subsidiary Sale of goods or services 5,000.00 Approved by the audit committee of the entity 1,615.40 187.20 1,591.50
36 Alkem Laboratories Limited Ascend Laboratories S.A. DE. CV Step down subsidiary Any other transaction Guarantee commission 100.00 Approved by the audit committee of the entity 0.80 0.00 0.00
37 Alkem Laboratories Limited Ascend Laboratories SpA Subsidiary Any other transaction Reimbursement of Expenses by us 500.00 Approved by the audit committee of the entity 99.50 7,487.70 8,318.80
38 Alkem Laboratories Limited Ascend Laboratories SpA Subsidiary Any other transaction Reimbursement of Expenses by party 300.00 Approved by the audit committee of the entity 100.20 169.30 338.60
39 Alkem Laboratories Limited Ascend Laboratories LLC Step down subsidiary Sale of goods or services 2,28,600.00 Approved by the audit committee of the entity 80,422.50 74,794.10 63,414.60
40 Alkem Laboratories Limited Ascend Laboratories LLC Step down subsidiary Any other transaction Royalty income 1,100.00 Approved by the audit committee of the entity 513.50 74,794.10 63,414.60
41 Alkem Laboratories Limited Ascend Laboratories LLC Step down subsidiary Any other transaction Services rendered 2,000.00 Approved by the audit committee of the entity 630.50 74,794.10 63,414.60
42 Alkem Laboratories Limited Ascend Laboratories LLC Step down subsidiary Any other transaction Reimbursement of Expenses by us 10,000.00 Approved by the audit committee of the entity 1,327.70 9,315.50 3,640.90
43 Alkem Laboratories Limited Pharma Network SpA Step down subsidiary Any other transaction Guarantee commission 100.00 Approved by the audit committee of the entity 6.30 0.00 12.20
44 Alkem Laboratories Limited Pharma Network SpA Step down subsidiary Any other transaction Reimbursement of Expenses by party 100.00 Approved by the audit committee of the entity 17.60 13.20 12.20
45 Alkem Laboratories Limited Pharmacor Limited Subsidiary Sale of goods or services 3,000.00 Approved by the audit committee of the entity 552.90 915.60 1,036.30
46 Alkem Laboratories Limited Pharmacor Limited Subsidiary Any other transaction Guarantee commission 100.00 Approved by the audit committee of the entity 0.80 0.00 0.00
47 Alkem Laboratories Limited Pharmacor Pty Limited Subsidiary Sale of goods or services 30,900.00 Approved by the audit committee of the entity 10,974.40 10,893.10 6,973.20
48 Alkem Laboratories Limited Pharmacor Pty Limited Subsidiary Any other transaction Guarantee commission 100.00 Approved by the audit committee of the entity 1.00 0.00 0.00
49 Alkem Laboratories Limited Pharmacor Pty Limited Subsidiary Any other transaction Reimbursement of Expenses by us 3,800.00 Approved by the audit committee of the entity 953.80 2,191.60 1,979.90
50 Alkem Laboratories Limited Pharmacor Pty Limited Subsidiary Any other transaction Services rendered 1,500.00 Approved by the audit committee of the entity 17.90 10,893.10 6,973.20
51 Alkem Laboratories Limited Pharmacor Pty Limited Subsidiary Any other transaction Reimbursement of Expenses by party 100.00 Approved by the audit committee of the entity 59.40 10,893.10 6,973.20
52 Alkem Laboratories Limited S&B Pharma LLC Step down subsidiary Any other transaction Reimbursement of expenses by us 500.00 Approved by the audit committee of the entity 0.00 704.20 158.30
53 Alkem Laboratories Limited S&B Pharma LLC Step down subsidiary Any other transaction Reimbursement of Expenses by party 500.00 Approved by the audit committee of the entity 86.90 0.00 98.70
54 Alkem Laboratories Limited The Pharmanetwork LLP Subsidiary Sale of goods or services 16,000.00 Approved by the audit committee of the entity 2,251.90 6,980.40 7,197.10 Investment 0 NA Unsecured Business Requirement Textual Information(1)
55 Alkem Laboratories Limited The Pharmanetwork LLP Subsidiary Any other transaction Reimbursement of expenses by us 500.00 Approved by the audit committee of the entity 150.80 0.00 287.50
56 Alkem Laboratories Limited The Pharmanetwork LLP Subsidiary Any other transaction Guarantee commission 100.00 Approved by the audit committee of the entity 2.70 0.00 0.00
57 Alkem Laboratories Limited Dr Meghna Singh Relatives of Key Managerial Personnel Any other transaction Consultancy fees 30.00 Approved by the audit committee of the entity 15.00 0.00 0.00
58 Alkem Laboratories Limited Dr Divya Singh Relatives of Key Managerial Personnel Any other transaction Consultancy fees 100.00 Approved by the audit committee of the entity 15.00 0.00 0.00
59 Alkem Laboratories Limited Mr Rajeev Kher Key Management Personnel Any other transaction Sitting fees and commission As per approval of Board of Directors or Shareholders of the entity as necessary 21.00 0.00 0.00
60 Alkem Laboratories Limited Mrs Madhurima Singh Key Management Personnel Any other transaction Rent expenses 100.00 Approved by the audit committee of the entity 9.90 0.00 0.00
61 Alkem Laboratories Limited Mr Sarvesh Singh Key Management Personnel Any other transaction Rent expenses 100.00 Approved by the audit committee of the entity 5.10 0.00 0.00
62 Alkem Laboratories Limited Dr Divya Singh Relatives of Key Managerial Personnel Any other transaction Rent expenses 100.00 Approved by the audit committee of the entity 5.70 0.00 0.00
63 Alkem MedTech Ortho Pvt Ltd (formerly known as Bombay Ortho Industries Pvt. Ltd.) Mr Harish Lad Subsidiary Any other transaction Reimbursement of Expenses by party Not Applicable 3.30 0.00 0.00
64 Alkem MedTech Ortho Pvt Ltd (formerly known as Bombay Ortho Industries Pvt. Ltd.) Mr Umesh Chatrala Subsidiary Any other transaction Professional fees Not Applicable 5.40 0.00 0.00
65 Alkem Medtech Private Limited Mr Arun Purwar Subsidiary Any other transaction Sitting fees As per approval of Board of Directors or Shareholders of the entity as necessary 0.00 0.00 0.00
66 Alkem Medtech Private Limited Mr Kaustav Banerjee Subsidiary Any other transaction Reimbursement of Expenses by party Not Applicable 2.30 0.00 0.00
67 Alkem Medtech Private Limited Alkem MedTech Ortho Pvt Ltd (formerly known as Bombay Ortho Industries Pvt. Ltd.) Subsidiary Investment As per approval of Board of Directors or Shareholders of the entity as necessary 0.00 0.00 10,856.50
68 Adroit Biomed Ltd Mr Sameer Paigankar Subsidiary Any other transaction Reimbursement of Expenses by party Not Applicable 3.60 0.00 0.00
69 Adroit Biomed Ltd Mr Sushant Raorane Subsidiary Any other transaction Professional fees Not Applicable 3.40 0.00 0.00
70 Adroit Biomed Ltd Mr Sushant Raorane Subsidiary Any other transaction Reimbursement of Expenses by party Not Applicable 1.10 0.00 0.00
71 Adroit Biomed Ltd Pharmaserve Health Care Pvt. Ltd. Subsidiary Purchase of goods or services Not Applicable 0.00 0.00 0.00
72 Adroit Biomed Ltd Nutragenix Healthcare Pvt. Ltd. Subsidiary Any other transaction Business Support service Not Applicable 0.00 0.00 0.00
73 Alkem Laboratories Limited Mr Manish Narang Key Management Personnel Remuneration As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 120.30 0.00 0.00
74 Alkem Laboratories Limited Mr Mritunjay Kumar Singh Key Management Personnel Remuneration As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 577.20 0.00 0.00
75 Alkem Laboratories Limited Mr Nitin Agrawal Key Management Personnel Remuneration As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 219.70 0.00 0.00
76 Alkem Laboratories Limited Mr Arun Purwar Key Management Personnel Any other transaction Sitting fees and commission As per approval of Board of Directors or Shareholders of the entity as necessary 1.20 0.00 0.00
77 Alkem Laboratories Limited Ms. Sangeeta Singh Key Management Personnel Any other transaction Sitting fees and commission As per approval of Board of Directors or Shareholders of the entity as necessary 1.10 0.00 0.00
78 Alkem Laboratories Limited Ms. Sudha Ravi Key Management Personnel Any other transaction Sitting fees and commission As per approval of Board of Directors or Shareholders of the entity as necessary 1.10 0.00 0.00
79 Alkem Laboratories Limited Mr Narendra Kumar Aneja Key Management Personnel Any other transaction Sitting fees and commission As per approval of Board of Directors or Shareholders of the entity as necessary 21.00 0.00 0.00
80 Alkem Laboratories Limited Mr. Sandeep Singh Key Management Personnel Remuneration As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 234.60 0.00 0.00
81 Alkem Laboratories Limited Mr Sarandhar Singh Relatives of Key Managerial Personnel Remuneration As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 335.00 0.00 0.00
82 Alkem Laboratories Limited Mr Sarvesh Singh Key Management Personnel Remuneration As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 236.70 0.00 0.00
83 Alkem Laboratories Limited Mr Satish Kumar Singh Relatives of Key Managerial Personnel Remuneration As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 341.70 0.00 0.00
84 Alkem Laboratories Limited Mr R L Shenoy Key Management Personnel Any other transaction Sitting fees and commission As per approval of Board of Directors or Shareholders of the entity as necessary 19.90 0.00 0.00
85 Alkem Laboratories Limited Ms Neela Bhattacherjee Key Management Personnel Any other transaction Sitting fees and commission As per approval of Board of Directors or Shareholders of the entity as necessary 17.40 0.00 0.00
86 Alkem Laboratories Limited Mr Diwakar Gupta Key Management Personnel Any other transaction Sitting fees and commission As per approval of Board of Directors or Shareholders of the entity as necessary 19.90 0.00 0.00
87 Alkem Laboratories Limited Mr Sujjain Talwar Key Management Personnel Any other transaction Sitting fees and commission As per approval of Board of Directors or Shareholders of the entity as necessary 19.00 0.00 0.00
88 Alkem Laboratories Limited Mr Srinivas Singh Key Management Personnel Remuneration As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 522.10 0.00 0.00
89 Alkem Laboratories Limited Mr Sarvesh Singh Key Management Personnel Any other transaction Reimbursement of Expenses by party Not Applicable 5.70 0.00 0.00
90 Alkem Laboratories Limited Mr. Sandeep Singh Key Management Personnel Any other transaction Commission As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 200.00 0.00 0.00
91 Alkem Laboratories Limited Mr. Sandeep Singh Key Management Personnel Any other transaction Reimbursement of Expenses by party Not Applicable 534.80 0.00 0.00
92 Alkem Laboratories Limited Mr Sarandhar Singh Relatives of Key Managerial Personnel Any other transaction Reimbursement of Expenses by party Not Applicable 13.60 0.00 0.00
93 Alkem Laboratories Limited Mr Srinivas Singh Key Management Personnel Any other transaction Reimbursement of Expenses by party Not Applicable 210.70 0.00 0.00
94 Alkem Laboratories Limited Mr Nitin Agrawal Key Management Personnel Any other transaction Reimbursement of Expenses by party Not Applicable 2.00 0.00 0.00
95 Alkem Laboratories Limited Dr Vikas Gupta Key Management Personnel Any other transaction Reimbursement of Expenses by party Not Applicable 1.00 0.00 0.00
96 Alkem Laboratories Limited Mr Basudeo Narain Singh Key Management Personnel Any other transaction Reimbursement of Expenses by party Not Applicable 6.00 0.00 0.00
97 Alkem Laboratories Limited Mr Manish Narang Key Management Personnel Any other transaction Reimbursement of Expenses by party Not Applicable 6.90 0.00 0.00
98 Ascend Laboratories, SpA Pharma Network SpA Subsidiary Sale of goods or services Not Applicable 2,135.70 2,047.20 403.50
99 Alkem Laboratories Limited Indchemie Health Specialities Private Limited Subsidiary Purchase of goods or services 15,000.00 Approved by the audit committee of the entity 2,835.30 1,301.20 1,028.10
100 Alkem Laboratories Limited Indchemie Health Specialities Private Limited Subsidiary Sale of goods or services 1,000.00 Approved by the audit committee of the entity 14.70 1,301.20 1,028.10
101 Alkem Laboratories Limited Indchemie Health Specialities Private Limited Subsidiary Any other transaction Services received 9,000.00 Approved by the audit committee of the entity 84.30 1,301.20 1,028.10
102 Alkem Laboratories Limited Indchemie Health Specialities Private Limited Subsidiary Any other transaction Rent Income 300.00 Approved by the audit committee of the entity 82.80 1,301.20 1,028.10
103 Alkem Laboratories Limited Enzene Biosciences Limited Subsidiary Purchase of goods or services 40,000.00 Approved by the audit committee of the entity 4,570.90 2,408.00 4,962.00
104 Alkem Laboratories Limited Enzene Biosciences Limited Subsidiary Any other transaction Royalty income 2,000.00 Approved by the audit committee of the entity 266.60 595.00 4,962.00
105 Alkem Laboratories Limited Enzene Biosciences Limited Subsidiary Any other transaction Guarantee commission 700.00 Approved by the audit committee of the entity 92.70 0.00 0.00
106 Alkem Laboratories Limited Galpha Laboratories Limited Affiliate Purchase of goods or services 800.00 Approved by the audit committee of the entity 311.90 159.10 132.00
107 Alkem Laboratories Limited Connect 2 Clinic Private Limited Subsidiary Any other transaction Services received 2,000.00 Approved by the audit committee of the entity 179.00 253.10 220.50
108 Alkem Laboratories Limited Alkem Foundation Subsidiary Any other transaction Donations given 4,500.00 Approved by the audit committee of the entity 2,670.50 0.00 0.00
109 Indchemie Health Specialities Private Limited Cachet Pharmaceuticals Private Limited Fellow Subsidiary Company Sale of goods or services Approved by the audit committee of the entity 415.10 34.20 195.70
110 Alkem Laboratories Limited Dr Vikas Gupta Key Management Personnel Remuneration As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 775.70 0.00 0.00
111 Alkem Laboratories Limited Mrs Madhurima Singh Key Management Personnel Remuneration As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 478.30 0.00 0.00
112 Indchemie Health Specialities Private Limited Mr Mritunjay Kumar Singh Key Management Personnel Any other transaction Rent expenses Not Applicable 0.80 0.00 0.00
113 Cachet Pharmaceuticals Private Limited Galpha Laboratories Limited Affiliate Purchase of goods or services Approved by the audit committee of the entity 54.70 38.20 31.00
114 Enzene Biosciences Limited Enzene Inc Subsidiary Investment Approved by the audit committee of the entity 13,741.50 20,660.00 37,004.00 Investment 0 NA Unsecured Business requirement Textual Information(2)
115 Enzene Biosciences Limited Enzene Inc Subsidiary Loan Approved by the audit committee of the entity 956.00 19,040.00 38,156.00 Loan 9.0500 7 Unsecured Business Requirements
116 Cachet Pharmaceuticals Private Limited Mr. Arunkumar Deshmukh Key Management Personnel Any other transaction Sitting fees As per approval of Board of Directors or Shareholders of the entity as necessary 0.50 0.00 0.00
117 The Pharma Network LLC Mr. Sandeep Singh Key Management Personnel Remuneration As per approval of Board of Directors. 428.40 0.00 0.00
118 Cachet Pharmaceuticals Private Limited Mr VIRENDRA V. YAGNIK Key Management Personnel Any other transaction Sitting fees As per approval of Board of Directors or Shareholders of the entity as necessary 0.40 0.00 0.00
119 Cachet Pharmaceuticals Private Limited Dr Anuja Sinha Key Management Personnel Any other transaction Sitting fees As per approval of Board of Directors or Shareholders of the entity as necessary 0.30 0.00 0.00
120 Indchemie Health Specialities Private Limited Mr Akhouri Maheshwari Prasad Key Management Personnel Any other transaction Sitting fees As per approval of Board of Directors or Shareholders of the entity as necessary 0.00 0.00 0.00
121 Indchemie Health Specialities Private Limited Mr R L Shenoy Key Management Personnel Any other transaction Sitting fees As per approval of Board of Directors or Shareholders of the entity as necessary 3.00 0.00 0.00
122 Indchemie Health Specialities Private Limited Mr Tiruvidaimarudhur Srivatsan Sivasha Key Management Personnel Any other transaction Sitting fees As per approval of Board of Directors or Shareholders of the entity as necessary 3.00 0.00 0.00
123 Indchemie Health Specialities Private Limited Mrs Shilpa Shashank Mulgaokar Key Management Personnel Any other transaction Sitting fees As per approval of Board of Directors or Shareholders of the entity as necessary 1.00 0.00 0.00
124 Indchemie Health Specialities Private Limited Mr Gautam Gulabchand Parekh Key Management Personnel Any other transaction Sitting fees As per approval of Board of Directors or Shareholders of the entity as necessary 0.00 0.00 0.00
125 Enzene Biosciences Limited Ms. Sangeeta Singh Key Management Personnel Any other transaction Sitting fees As per approval of Board of Directors or Shareholders of the entity as necessary 1.60 0.00 0.00
126 Enzene Biosciences Limited Ms. Sudha Ravi Key Management Personnel Any other transaction Sitting fees As per approval of Board of Directors or Shareholders of the entity as necessary 2.60 0.00 0.00
127 Alkem Laboratories Limited Ascend Laboratories LLC Subsidiary Any other transaction Guarantee commission 200.00 Not Applicable 25.90 0.00 0.00
128 Alkem Laboratories Limited Ascend Laboratories LLC Subsidiary Any other transaction Reimbursement of Expenses by party 500.00 Approved by the audit committee of the entity 98.80 0.00 0.00
129 Alkem Laboratories Limited Enzene Biosciences Limited Subsidiary Any other transaction Reimbursement of expenses by party Not Applicable 1,300.20 201.00 4,962.00
130 Alkem Laboratories Limited Enzene Biosciences Limited Subsidiary Any other transaction Profit Share on goods sold in tender 32.00 Ratified by the audit committee of the entity 32.00 27-05-2026 32.00 0.00 0.00
131 Alkem Laboratories Limited Cachet Pharmaceuticals Private Limited Subsidiary Sale of goods or services 2,000.00 Approved by the audit committee of the entity 0.00 0.00 170.00
132 Alkem Laboratories Limited Alkem Medtech Private Limited Subsidiary Any other transaction Reimbursement of Expenses by party 2,000.00 Approved by the audit committee of the entity 1,999.40 2.30 2,297.20
133 Alkem Laboratories Limited Alkem Medtech Private Limited Subsidiary Any other transaction Reimbursement of Expenses by party 23.00 Ratified by the audit committee of the entity 23.00 27-05-2026 23.00 0.00 0.00
134 Alkem Laboratories Limited Alkem Medtech Private Limited Subsidiary Any other transaction Reimbursement of expenses by us 500.00 Approved by the audit committee of the entity 0.00 2.30 2,297.20
135 Alkem Laboratories Limited Alkem Medtech Private Limited Subsidiary Any other transaction Business Support service 1,000.00 Approved by the audit committee of the entity 279.10 0.00 0.00
136 Alkem Laboratories Limited Alkem Medtech Private Limited Subsidiary Any other transaction Royalty income 500.00 Approved by the audit committee of the entity 3.40 0.00 0.00
137 Alkem Laboratories Limited Enzene Biosciences Limited Subsidiary Investment As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 30,000.00 0.00 30,000.00 Investment 0 NA Unsecured Business requirement Textual Information(3)
138 Alkem Laboratories Limited Ascend Laboratories Limited Subsidiary Investment As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 463.00 0.00 463.00 Investment 0 NA Unsecured Business requirement Textual Information(4)
139 Alkem Laboratories Limited Adroit Biomed Ltd Subsidiary Investment As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 14,395.00 0.00 14,395.00 Investment 0 NA Unsecured Business requirement Textual Information(5)
140 Alkem Laboratories Limited Alixer Nexgen Therapeutics Limited Subsidiary Investment As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 0.00 20.00 2,520.00 Investment 0 NA Unsecured Business requirement Textual Information(6)
141 Alkem Laboratories Limited Alixer Nexgen Therapeutics Limited Subsidiary Any other transaction Reimbursement of expenses by us 2,100.00 Approved by the audit committee of the entity 852.40 97.50 575.70
142 Alkem Laboratories Limited Alixer Nexgen Therapeutics Limited Subsidiary Any other transaction Reimbursement of expenses by party 10,000.00 Approved by the audit committee of the entity 81.40 97.50 575.70
143 Alkem Laboratories Limited Alixer Nexgen Therapeutics Limited Subsidiary Any other transaction Business Support service 1,500.00 Approved by the audit committee of the entity 16.90 0.00 17.00
144 Alkem Laboratories Limited Alkem Wellness Limited Subsidiary Investment As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 0.00 500.00 65,500.00 Investment 0 NA Unsecured Business requirement Textual Information(7)
145 Alkem Laboratories Limited Alkem Wellness Limited Subsidiary Any other transaction Reimbursement of expenses by us 5,000.00 Approved by the audit committee of the entity 745.10 302.80 0.00
146 Ascend Laboratories, SpA Pharmacor SPA Subsidiary Sale of goods or services Not Applicable 3,979.00 0.00 4,096.10
147 Alkem Laboratories Limited Indchemie Health Specialities Private Limited Subsidiary Any other transaction Reimbursement of Expenses by party 100.00 Approved by the audit committee of the entity (9.10) 0.00 0.00
148 Alkem Laboratories Limited Indchemie Health Specialities Private Limited Subsidiary Any other transaction Dividend Received from subsidiary As per approval of Board of Directors or Shareholders of the entity as necessary 0.00 0.00 0.00
149 Alkem Laboratories Limited Connect 2 Clinic Private Limited Subsidiary Any other transaction Reimbursement of expenses by us 500.00 Approved by the audit committee of the entity 0.00 0.00 220.50
150 Alkem Laboratories Limited Connect 2 Clinic Private Limited Subsidiary Any other transaction Reimbursement of Expenses by party 500.00 Approved by the audit committee of the entity 3.30 0.00 0.00
151 Alkem Laboratories Limited Pharmacor SPA Subsidiary Any other transaction Guarantee commission 100.00 Approved by the audit committee of the entity 4.40 0.00 1.90
152 Alkem Laboratories Limited Alkem Medtech Private Limited Subsidiary Any other transaction Rent Income 50.00 Approved by the audit committee of the entity 0.50 2.30 2,297.20
153 Alkem Laboratories Limited Alkem Wellness Limited Subsidiary Any other transaction Rent Income 500.00 Approved by the audit committee of the entity 102.70 302.80 13,172.60
154 Alkem Laboratories Limited Alkem Wellness Limited Subsidiary Sale of goods or services 40,000.00 Approved by the audit committee of the entity 10,159.10 0.00 13,175.60
155 Alkem Laboratories Limited Alkem Wellness Limited Subsidiary Any other transaction Reimbursement of Expenses by party 2,500.00 Approved by the audit committee of the entity 2,384.70 0.00 13,175.60
156 Alkem Laboratories Limited Alkem Wellness Limited Subsidiary Purchase of goods or services 15,000.00 Approved by the audit committee of the entity 14.00 0.00 0.00
157 Alkem Laboratories Limited Alkem Wellness Limited Subsidiary Any other transaction Services rendered 10,000.00 Approved by the audit committee of the entity 494.10 0.00 13,175.60
158 Alkem Laboratories Limited Alkem Wellness Limited Subsidiary Any other transaction Business Support service 4,000.00 Approved by the audit committee of the entity 1,547.30 0.00 13,175.60
159 Alkem Laboratories Limited Alkem Wellness Limited Subsidiary Any other transaction Royalty income 500.00 Approved by the audit committee of the entity 265.00 0.00 13,175.60
160 Alkem Laboratories Limited Alkem Wellness Limited Subsidiary Any other transaction Collection on behalf of Alkem Wellness by Alkem Laboratories Ltd 1,00,000.00 Approved by the audit committee of the entity 56,645.00 0.00 0.00
161 Alkem Laboratories Limited Alkem Wellness Limited Subsidiary Any other transaction Payment on behalf of Alkem Wellness by Alkem Laboratories Ltd 50,000.00 Approved by the audit committee of the entity 22,196.00 0.00 0.00
162 Alkem Laboratories Limited Alkem Wellness Limited Subsidiary Any other transaction Security Deposit received Not Applicable 0.00 0.00 50.10
163 Alkem Laboratories Limited Adroit Biomed Ltd Subsidiary Any other transaction Reimbursement of Expenses by party 200.00 Approved by the audit committee of the entity 27.90 0.00 0.00
164 Alkem Laboratories Limited Adroit Biomed Ltd Subsidiary Purchase of goods or services 2,500.00 Approved by the audit committee of the entity 408.60 0.00 412.50
165 Alkem Laboratories Limited Adroit Biomed Ltd Subsidiary Any other transaction Business Support service 500.00 Approved by the audit committee of the entity 78.30 0.00 78.00
166 Alkem Laboratories Limited Ascend Laboratories Limited Subsidiary Any other transaction Reimbursement of expenses by us 100.00 Approved by the audit committee of the entity 99.90 0.00 99.90
167 Cachet Pharmaceuticals Private Limited Alkem Wellness Limited Fellow Subsidiary Company Sale of goods or services Approved by the audit committee of the entity 7,199.00 0.00 2,871.40
168 Indchemie Health Specialities Private Limited Alkem Wellness Limited Fellow Subsidiary Company Any other transaction Services rendered Not Applicable 1,741.00 0.00 311.60
169 Cachet Pharmaceuticals Private Limited Alkem Wellness Limited Fellow Subsidiary Company Any other transaction Services rendered Not Applicable 405.00 0.00 2,871.40
170 Pharmacor SPA Ascend Laboratories SpA Fellow Subsidiary Company Any other transaction Reimbursement of expenses by us Not Applicable 215.00 0.00 0.00
171 Ascend Laboratories, SpA Ascend Laboratories S.A. DE. CV Fellow Subsidiary Company Any other transaction Advance given Not Applicable 142.00 0.00 0.00
172 Ascend Laboratories S.A. DE. CV Ascend Laboratories SpA Fellow Subsidiary Company Any other transaction Advance repaid Not Applicable 142.00 0.00 0.00
173 Enzene Biosciences Limited Enzene Inc Fellow Subsidiary Company Any other transaction Reimbursement of expenses by us Not Applicable 10.00 0.00 3.00
174 Ascend Laboratories LLC Ascend Laboratories Limited Fellow Subsidiary Company Any other transaction Advance given Not Applicable 63.00 0.00 0.00
175 Ascend Laboratories Limited Ascend Laboratories LLC Fellow Subsidiary Company Any other transaction Advance repaid Not Applicable 63.00 0.00 0.00
176 Ascend Laboratories LLC Mr. Sandeep Singh Fellow Subsidiary Company Any other transaction Advance given Not Applicable 158.00 0.00 0.00
177 Mr. Sandeep Singh Ascend Laboratories LLC Fellow Subsidiary Company Any other transaction Advance repaid Not Applicable 158.00 0.00 0.00
178 Enzene Biosciences Limited Enzene Inc Fellow Subsidiary Company Sale of goods or services Not Applicable 6.00 0.00 40.00
179 Alkem Medtech Private Limited Alkem MedTech Ortho Pvt Ltd (formerly known as Bombay Ortho Industries Pvt. Ltd.) Fellow Subsidiary Company Any other transaction Royalty income Not Applicable 7.00 0.00 1,522.00
180 Alkem Medtech Private Limited Alkem MedTech Ortho Pvt Ltd (formerly known as Bombay Ortho Industries Pvt. Ltd.) Fellow Subsidiary Company Any other transaction Business Support service Not Applicable 1,506.00 0.00 1,522.00
Total value of transaction during the reporting period 3,28,480.70



Text Block

Textual Information(1) Equity Investment
Textual Information(2) Equity Investment
Textual Information(3) Equity Investment
Textual Information(4) Equity Investment
Textual Information(5) Equity Investment
Textual Information(6) Equity Investment
Textual Information(7) Equity Investment